Immunohistochemistry

Histologix has extensive experience in providing high-throughput IHC screening of normal and diseased tissue using an extensive range of antibodies directed against cell signalling proteins.

Angiogenisis Studies

In order to demonstrate the effects of antiangiogenic therapies, it is necessary to be able to stain and measure newly formed blood vessels.

By measuring the MicroVessel Density (MVD) using our image analysis software we can identify changes to the size/number of stained blood vessels following therapy within given samples.

Target Validation and Target Distribution Studies

It is important to be able to demonstrate the presence of a particular target in a disease process. Using optimised IHC and ISH assays Histologix can detect the presence of, and is able to quantify the levels of target present within cell lines, patient tissue or xenografts. 

Target distribution is also useful data to generate as part of the validation process.  Using IHC or ISH it will be possible to mine expression data from archive material of tumour populations. This will provide useful information when identifying therapy target or choosing the most likely antibody clones to develop as prognostic/predictive markers.  The use of tissue microarrays (TMA’s) from specific disease types is another useful way to obtain relevant data from many samples which can be combined with the necessary clinical history and patient follow-up data.

Cell Proliferation and Apoptotic Studies

Abnormal cell proliferation is fundamental in tumourigenesis. Being able to identify and measure cell proliferation in pre and post therapeutic tissues is an important endpoint in determining drug therapy efficacy and in turn may be linked to apoptosis. 

A number of proliferative markers used for this purpose have been optimised by Histologix, along with quantitation using the Halo™ image analysis software will accurately and consistently measure proliferative index (% positive cells from a total of all cells).

BioSimilars

With a number of the original biotherapeutic molecules soon to be coming out of license there is a significant amount of interest in demonstrating similarities to generic versions of these drugs, eg. Rituximab, Avastin and Herceptin.

One of the many ways to demonstrate similarities between the generic and original versions is to generate xenografts from the relevant over-expressing tumour cell lines in SCID or Nude mice and to treat these with the relevant compounds using IHC/ISH to identify, quantify and compare data using Halo™ image analysis software.

Image Analysis

As technology evolves Histologix has invested internally and now offers the latest, most intuitive and highly functional image analysis software.

Find out more

News & resources